Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 10:06 ET | Source: Genmab A/S

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 19, 2026, the Annual Report for 2025 was approvedDischarge was given to the Board of Directors and the Executive Management...
March 19, 2026 09:00 ET | Source: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in...
March 19, 2026 09:00 ET | Source: Evaxion

Notice to convene Evaxion’s Annual General Meeting

COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its...
March 19, 2026 08:31 ET | Source: Humacyte, Inc

Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at...
March 19, 2026 08:30 ET | Source: Humacyte, Inc

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results...
March 19, 2026 08:00 ET | Source: Grace Therapeutics, Inc.

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage,...
March 19, 2026 08:00 ET | Source: Immutep Limited

Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR...
March 19, 2026 08:00 ET | Source: Causeway Therapeutics Ltd

Causeway Therapeutics Presents Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis at RNA Leaders Europe 2026

Causeway Therapeutics announces the presentation of data from its Phase 2 clinical trial evaluating TenoMiR® (CWT-001), at RNA Leaders Europe 2026.
March 19, 2026 08:00 ET | Source: INmune Bio, Inc.

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 ...
March 19, 2026 08:00 ET | Source: Chemomab Therapeutics Ltd.

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance along with preparations to launch the PSC Phase 3 trial.